Seyltx is a late clinical-stage pharmaceutical company leveraging new insights into how the brain functions to selectively target the "master switch" of the cough reflex to address refractory chronic cough - a condition that 4-5 million people in the US alone suffers from.
Company Details
- Employees
- 3
- Founded
- 2023
- Address
- Refractory Chronic Cough - A Condition That 4-5 Million People In The Us Alone Suffers From.
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.seyltx.com
- Keywords
- Collabrity.
Seyltx Questions
Seyltx's website is http://www.seyltx.com
Seyltx's LinkedIn profile is https://www.linkedin.com/company/seyltx
Seyltx has
3 employees.
View email and phone details for 3
employees at Seyltx.
Seyltx's industry is
Pharmaceutical Manufacturing
Seyltx's top competitors are
Axalbion Therapeutics Limited,
Cellara Biotechnology,
Neurop, Inc.,
Gambit Bio Llc,
Collabrity,
Peptilogics,
Paratek Pharmaceuticals,
Wobble Genomics Ltd,
Archer Precision Medicine Advisory Llc,
Biogenesis.
Seyltx's categories are Pharmaceutical Manufacturing
Seyltx's founding year is 2023
